HCA Healthcare, Inc. HCA
Healthcare · Medical Care Facilities · United States · S&P 500
Based on the available data, HCA Healthcare, Inc. gets an algorithmic score of 54/100. It trades at 431.63 $, with a sideways/transition technical trend (RSI 56.3) and 31.0% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Attractive free-cash-flow yield (8.0%).
- Low beta (0.34): defensive profile.
- Meaningful dividend (72.00%).
Weaknesses
- —
Fundamentals
| P/E | 14.47 |
| Forward P/E | 13.48 |
| PEG | 1.34 |
| P/B | -14.16 |
| EV/EBITDA | 9.35 |
| P/S | 1.23 |
| ROA % | 12.29 |
| Gross margin % | 42.58 |
| Operating margin % | 15.16 |
| Net margin % | 8.77 |
| Revenue growth % (y/y) | 8.70 |
| Earnings growth % (y/y) | 11.60 |
| Revenue CAGR % | 7.87 |
| Earnings CAGR % | 6.33 |
| Current ratio | 0.99 |
| FCF yield % | 8.03 |
| Dividend yield % | 72.00 |
| Payout % | 10.06 |
Returns
| 1 month | +3.5 % |
| 3 months | +10.9 % |
| 6 months | -7.4 % |
| YTD | -7.8 % |
| 1 year | +3.7 % |
| 3 years | +75.1 % |
| 5 years | +75.9 % |
Risk
| 1-year volatility | 31.0 % |
| Beta | 0.34 |
| 5-year max drawdown | -39.5 % |
| Sharpe 1A | 0.14 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.